Phil’s Journal: C2N’s Alzheimer’s Blood Test
By
Phil Gutis
| August 10th, 2023
It was 7:20 a.m. and Joel Braunstein, co-founder and CEO of C2N Diagnostics, was about to start his second meeting of the day. C2N…
Phil’s Journal: On ‘Entering the Era of Alzheimer’s Treatment’
By
Phil Gutis
| July 19th, 2023
AMSTERDAM —In the data presented at this week’s Alzheimer’s Association International Conference in Amsterdam, donanemab has been shown to slow development of memory and…
Phil’s Journal: Will New Alzheimer’s Drugs Work for As Well for Women as They Do for Men?
By
Phil Gutis
| July 18th, 2023
As I prepared to board the plane to Amsterdam for the Alzheimer’s Association International Conference, an email from the news site Axios caught my…
Phil’s Journal: Dispatch from AAIC, Day One
By
Phil Gutis
| July 17th, 2023
AMSTERDAM — When we arrived at the Rijks Museum, the home of Netherland’s most cherished artwork and cultural heritage, the halls were pretty empty…
Phil’s Journal: Before AAIC In Amsterdam, Leading Alzheimer’s Advocates Weigh In
By
Phil Gutis
| July 14th, 2023
A record number of people — 6,524 and counting — are expected in Amsterdam next week for the annual Alzheimer’s Association International Conference. As…
Phil’s Journal: What Is ‘Quality of Life?’ A Sad Farewell and a Tough Deciscion
By
Phil Gutis
| July 13th, 2023
We arrived at the emergency vet at 1 a.m. Our 10-month-old kitten, Pippin, had started breathing oddly earlier in the day but we thought…
Phil’s Journal: Legos, Lewy Body Symptoms, and, Maybe, the End of Aduhelm Access
By
Phil Gutis
| March 20th, 2023
Growing up, I wanted to be an architect. It wasn’t until I realized how much math was involved that those initial dreams died a…
Phil’s Journal: After 17 Marathons, Taking Up the Torch Again for Brain Health
By
Phil Gutis
| January 25th, 2023
Phil Gutis, a reporter and Being Patient columnist living with early-onset Alzheimer’s, reflects on his years of marathon running — and how, when it…
Phil’s Journal: Better Cognitive Assessments Are On the Way—I Tried One
By
Being Patient
| January 19th, 2023
I first saw the briefcase-sized computer monitor at the Alzheimer’s Association’s conference last summer in San Diego. Tom O’Neill, the president of a company…
Phil’s Journal: Another Alzheimer’s Drug, Lecanemab, Wins Early Approval—So, What Now?
By
Phil Gutis
| January 6th, 2023
I received my diagnosis of early Alzheimer’s in July 2016 through participation in a clinical trial for Biogen’s aducanumab (now known as Aduhelm). Except…
Phil’s Journal: Meet New Alzheimer’s Association CEO Joanne Pike
By
Phil Gutis
| January 5th, 2023
An Offer He Couldn’t Refuse: Reporter Phil Gutis interviews Joanne Pike on her first day as CEO of the Alzheimer’s Association As any reporter…
Phil’s Journal: A Note on Gratitude and Giving
By
Phil Gutis
| November 29th, 2022
Journalist and Alzheimer’s advocate Phil Gutis, who is living with early onset Alzheimer’s, shares some wisdom this Giving Tuesday. Another Thanksgiving has come and…
Phil’s Journal: Dog Dementia, or Bea’s Story
By
Phil Gutis
| September 29th, 2022
Sometimes I look up and see my future staring at me, wagging her tail. Her name is Beatrice. She’s a 16-year-old cattle dog mix…
Phil’s Journal: Why Voices of Alzheimer’s? Because ‘Silence Equals Death’
By
Phil Gutis
| September 21st, 2022
During the height of the AIDS crisis 35 years ago, a few hundred people gathered one night in the NYC Lesbian and Gay Community…
Phil’s Journal: An IRL Example of Racism’s Affects on Cognition
By
Phil Gutis
| September 1st, 2022
The setting could not have been less threatening. I was sitting in the press room on the last day of the Alzheimer’s Association International…